Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Gryphon Bio logo — Diagnostic-Powered Therapeutics for Brain Health

Gryphon Bio

Diagnostic-Powered Therapeutics for Brain Health

Founded 2018 United States South San Francisco, United States 7 employees Grant Total: $13.12M Biotechnology, Health Care

General Information

Company Name Gryphon Bio
Founded Year 2018
Location United States South San Francisco, United States +1
Employees 7
Industries Biotechnology, Health Care
Funding Stage Grant
Social

Get notified when Gryphon Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Gryphon Bio

Gryphon Bio is an early-stage company with a mission to develop and market the first diagnostic-powered therapeutics for brain health. Founded in 2018 and headquartered in the United States, Gryphon Bio aims to harness their co-founders' discovery of waves of brain molecules in the blood as novel therapeutic targets. Their groundbreaking research in "brain proteomic” over the past 20 years has led to the identification of brain-specific proteins with blood levels that change over time. The company's vision is to pioneer diagnostic-powered therapeutics to improve the lives of patients. Gryphon Bio received a significant $2.50M grant investment on 29 October 2023. As a player in the Biotechnology and Health Care industries, Gryphon Bio is poised to make a substantial impact on the future of brain health diagnostics and treatment.

Taxonomy: Brain health, Diagnostic-powered therapeutics, Biomarker, Proteomics, Healthcare innovation, Medical research, Neuroscience, Start-up, Investment potential

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• - 29 Oct 2023
Grant •••••• - 29 Oct 2023
Grant •••••• - 29 Oct 2023
Grant •••••• - 29 Oct 2023
Corporate Round •••••• - 14 Feb 2022

View All 9 Funding Rounds

Gryphon Bio Alternatives & Competitors

Gryphon Bio vs
Owl Therapeutics
Owl Therapeutics United States

Unlocking Wisdom for Brain Health

2 employees
Biopharma
Gryphon Bio vs
BBB Therapeutics
BBB Therapeutics The Netherlands

Combines existing drugs with it's proprietary for enhanced drug delivery across the blood-brain barr...

Unknown
21 employees
Biopharma, Biotechnology
Gryphon Bio vs
ABCDx SA
ABCDx SA Spain

Creating the future of point-of-care brain injury diagnostics by turning smartphones into medical de...

Series Unknown
14 employees
Health Care

FAQ About Gryphon Bio

Diagnostic-Powered Therapeutics for Brain Health
Gryphon Bio was founded in 2018.
Gryphon Bio is headquartered in South San Francisco, United States.
Gryphon Bio operates in the following industries: Biotechnology, Health Care.
Gryphon Bio has approximately 7 employees.
Gryphon Bio has completed 9 funding rounds, raising a total of $13.12M. The latest funding stage is Grant.
Top alternatives and competitors to Gryphon Bio include Owl Therapeutics, BBB Therapeutics, ABCDx SA, Evanesc Therapeutics, SiNON Nano Sciences . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gryphon Bio and Owl Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Gryphon Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes